How do tumor-on-a-chip models compare to traditional drug testing methods in terms of their effectiveness in improving personalized cancer treatment protocols?

Tumor-on-a-chip models offer advanced capabilities over traditional methods by simulating the tumor microenvironment and improving drug response predictions. However, direct comparative evidence is limited, and challenges in scalability and integration remain before widespread clinical adoption.